MHRA Enforcement Powers under UK MDR 2002 Part VII

1. Key takeaways

The MHRA (Medicines and Healthcare products Regulatory Agency) is an executive agency of the Department of Health and Social Care (DHSC) of the United Kingdom, responsible for medical device regulation across the United Kingdom and acting as the competent authority in Northern Ireland. Its enforcement powers are conferred by Part VII of the UK MDR 2002, including regulation 61 (enforcement), regulation 62 (compliance notices) and regulation 63 (restraint notices), supported by further provisions such as regulation 64 (decision notices) and regulation 65 (a centralised record system). Understanding this toolkit matters for planning: enforcement under the British system arrives in stages, and the stage at which a company responds determines how far a matter escalates. Companies that treat the first notice as routine correspondence often lose the opportunity to contain the issue within the earliest, least disruptive stage of the process.

2. Legal basis

The enforcement provisions and the fee provision that intersects with them are as follows:

• UK MDR 2002 (SI 2002/618, as amended): Part VII, regulation 59 (interpretation), regulation 60 (the status of the UKRP), regulation 61 (enforcement), regulation 62 (compliance notices), regulation 63 (restraint notices), regulation 64 (decision notices), regulation 65 (a centralised record system), regulation 67 (review).
• The Medical Devices (Fees Amendment) Regulations 2026 (SI 2026/197): regulation 3 inserts regulation 53(5) — a device must not be placed on the market by a person who has not paid the fees due.

Together these provisions show two distinct pressure points: the graduated enforcement powers that address non-compliant devices, and the fee provision that ties market access itself to the settlement of accounts. Both should appear on the compliance radar, because they are invoked by different triggers and demand different internal responses.

The standing of the UKRP under regulation 60 also deserves attention when mapping exposure. Because the responsible person is the addressee that authorities in Great Britain approach first, correspondence quality — complete records, current registration data, accurate labelling claims — determines how much of a query reaches the manufacturer directly. A well-maintained UKRP arrangement filters routine matters; a neglected one amplifies them, since every documentation gap becomes a question that the agency must put to somebody.

3. Expert insights

Insight 1: enforcement is graduated, not immediate. The compliance notices of regulation 62 and the restraint notices of regulation 63 form a progression: the former require the responsible person to remedy non-conformities within a specified period, while the latter can directly restrain the supply, placing on the market or putting into service of a device. The speed of a company’s response after receiving a compliance notice often determines whether the matter escalates. Treating the compliance notice as the final warning rather than an administrative formality is the posture that minimises both regulatory and commercial damage.

Insight 2: fee compliance has been written into market access itself. Regulation 53(5), inserted by SI 2026/197, provides that no person may place a device on the market unless all fees due under that provision have been paid, whether or not those fees relate to the specific device in question. The consequence is striking: an unpaid fee attributable to one device can block the lawful placing on the market of an entire product line. Fee ledgers therefore cease to be a finance department matter and become a market access control, deserving the same rigour and the same review cadence as certificates and registrations.

Insight 3: the MHRA monitors safety signals through multiple channels. Beyond vigilance reports, the MHRA collects safety information through mechanisms such as the Yellow Card scheme and, as described in official announcements, has strengthened its post-market surveillance activity. In the CE long-term recognition decision of 21 October 2026, officials expressly emphasised that the decision runs alongside the already strengthened post-market surveillance and reporting requirements. Manufacturers should therefore assume that signals reaching the MHRA from any channel can prompt questions, and should be ready to reconcile external reports with their own vigilance records.

4. Practical recommendations

GRZAN recommends merging the fee ledger, the registration ledger and the vigilance ledger into a single quarterly compliance review, with a named owner and an internal deadline of 48 hours for responding to any correspondence from the MHRA. For companies with established sales in the United Kingdom, a response plan for compliance notices should be drafted in advance, covering three lines at once: the technical argumentation that supports the device’s conformity, the corrective actions that can be offered, and the communication line towards distributors and customers. Preparing these materials before any notice arrives converts a regulatory event from an improvised scramble into a managed process with predictable outcomes.

The 48-hour target is not merely symbolic. Early responses preserve options: remediation offered within days of a compliance notice is usually accepted as cooperation, while the same remediation offered after escalation reads as concession under pressure. The review cadence also shortens the discovery window for fee arrears under regulation 53(5), so that a blocked product line is identified in a quarterly exercise rather than at the moment a shipment is prepared, when the cost of delay is highest.

5. Verification checklist

• □ An internal response owner and deadline for MHRA correspondence have been designated
• □ The fee, registration and vigilance ledgers are linked in a joint review mechanism
• □ The graduated enforcement logic of regulation 62 and regulation 63 is understood
• □ No unpaid fees are blocking market access under regulation 53(5)
• □ External safety signals such as the Yellow Card scheme are included in monitoring processes

Legal information verified as of 29 October 2026.

GRZAN supports manufacturers with the following services for the United Kingdom market:

• Appointment of the UK Responsible Person (UKRP) and signature support for the letter of authorisation
• End-to-end MHRA registration (DORS) filing and account lifecycle management
• Device classification determination, GMDN code selection and annual registration fee estimation
• Dual-track design for Great Britain and Northern Ireland, including UK(NI) solutions
• Post-market surveillance (PMS) system setup, PMSR/PSUR preparation and vigilance report submission
• Emergency response to serious incidents and field safety corrective actions (FSCA)
• Monitoring of UK regulatory changes and compliance gap assessment

GRZAN provides end-to-end MHRA registration and compliance support for manufacturers entering the United Kingdom market, covering every stage from market entry planning through post-market obligations. For enquiries, contact info@grzanglobal.com.